Indications: Treatment of HIV infection in combination with other agents. Contraindications: Known hypersensitivity. Dosage: 600 mg po q12h with food following two week dose escalation regimen (day 1 and 2: 300 mg po bid; days 3-5: 400 mg po bid; days 6-13: 500 mg po bid). When coadministered as pharmacologic booster with other protease inhibitors, dosage is reduced. There are many potential drug interactions, some of which require dosage modification; see Physicians Desk Reference or package insert for more information. Toxicity: Gastrointestinal intolerance, circumoral paresthesias, abnormal liver function tests. Pregnancy category B.
A protease inhibitor first approved by FDA in 1996 for use alone or in combination with nucleoside analogs for the treatment of HIV infection in adults and children 2 years of age and older.
A drug that belongs to the family of drugs called protease inhibitors. It interferes with the ability of a virus to make copies of itself.
a medicine that your healthcare provider may prescribe that increases the amount of LEXIVA in your body. This may help decrease the chances of the virus becoming resistant to some of your HIV medicines.
Protease inhibitor used in combination with other antiretroviral agents for the treatment of HIV; also known as RTV. Generic name for NorvirĀ®.
Ritonavir, with trade name Norvir® (Abbott Laboratories), is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS.